Addiction Toxicology Case Conference - January 2025

Contains 5 Component(s)

Benzodiazepine Tapering & Discontinuation Discussion

Friday, January 10, 2025
1:00-2:00pm ET

Case 1: Novel Synthetic Benzodiazepine Overdose

Case 2: Elderly Patient on Diazepam Presents with Acute Psychosis and Delerium

Learning Objectives

1. Demonstrate knowledge of benzodiazepine tapering and discontinuation discussions.

2. Describe the risks associated with long-term benzodiazepine use.

Continuing Education

1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.

About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.

This webinar is free and open to the public.

Maryann Amirshahi, PharmD, MD, MPH, PhD, FACMT

Emergency Medicine Attending Physician, Professor Of Emergency Medicine

MedStar Washington Hospital Center, Georgetown University Hospital

Dr. Maryann Amirshahi is a Professor of Emergency Medicine at Georgetown University School of Medicine and practices clinically at MedStar Washington Hospital Center, where she specializes in toxicology, addiction care, and emergency medicine. She holds a PharmD and medical degree, alongside an MPH focusing on environmental and occupational health, and a PhD in pharmacology and public health. Dr. Amirshahi is board-certified in emergency medicine, medical toxicology, addiction medicine, and clinical pharmacology, and is a registered pharmacist with over a decade of practice. Nationally recognized, she serves on the Board of Directors for the American College of Medical Toxicology. With nearly 200 peer-reviewed publications, her research spans medication safety, drug shortages, addiction treatment, and prescription drug misuse.

Maureen Boyle, PhD

Chief Quality and Science Officer

American Society of Addiction Medicine (ASAM)

Maureen Boyle, PhD, is the Chief Quality and Science Officer at the American Society of Addiction Medicine (ASAM), where she oversees the development of clinical guidelines and tools to support the implementation of evidence-based practices in addiction treatment. She provides strategic leadership for the ASAM Criteria Suite of products, including ASAM CONTINUUM, the ASAM Level of Care Certification Program, and the ASAM Criteria textbook. With over 20 years of experience in research, public health, and policy, Dr. Boyle has held key leadership roles at the Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institute on Drug Abuse (NIDA). She earned her Ph.D. in Neuroscience from the Washington University School of Medicine, completed a postdoctoral fellowship at the Allen Institute for Brain Science, and is an alumna of the AAAS Science and Technology Policy Fellowship.

Emily Brunner, MD, DFASAM

Regional Director; Medical Director

Region VI, ASAM; Gateway Recovery Center

Dr. Emily Brunner is a board-certified family medicine physician and distinguished fellow in addiction medicine, specializing in trauma-informed, compassionate care for substance use disorders. She serves as Medical Director of Gateway Recovery and Recovering Hope and conducts trainings for the Hazelden Betty Ford Foundation. A recognized leader, she has held positions with the Minnesota Society of Addiction Medicine and currently serves on the national board of the American Society of Addiction Medicine. Dr. Brunner is a passionate advocate for expanding access to medications for opioid use disorder and improving care for patients with substance use disorders across the healthcare system. Named a Top Doctor in addiction medicine by Minnesota Magazine in 2020 and 2021, she also has a clinical interest in internet gaming and gambling disorders.

Alex Krotulski, PhD

Associate Director of Toxicology & Chemistry

The Center for Forensic Science Research and Education

Dr. Alex J. Krotulski serves as a Director at the Center for Forensic Science Research and Education (CFSRE) working in the areas of forensic toxicology and forensic chemistry and is the Program Manager for NPS Discovery, the CFSRE’s drug early warning system and flagship program for the identification and characterization of new and emerging synthetic drugs. Dr. Krotulski is a chemist by training and practices as a forensic toxicologist. Dr. Krotulski holds faculty appointment and serves as the Program Director for the Thomas Jefferson University Master of Science in Forensic Toxicology (MSFT) program and is an Senior Associate Editor for the Journal of Analytical Toxicology.

Timothy J. Wiegand, MD, FACMT, DFASAM (Moderator)

Director and CEO, Toxicology Consulting

Medicine, Addiction Toxicology Consulting PLLC, ASAM President Elect (2025-2027)

Dr. Tim Wiegand is the Director of Toxicology Consults and President of CMO Medicine and Toxicology & Addiction Consulting. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.

Continuing Education

Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.

Nurses
Credit being awarded: 1.25 ANCC contact hours.

Commercial Support
There is no commercial support for this activity.

Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.
Maryann Amirshahi, MD, PharmD, PhD, Faculty: has nothing to disclose
Maureen Boyle, PhD, Faculty: has nothing to disclose
Emily Brunner, MD, Faculty: has nothing to disclose
Alex Krotulski, PhD, Faculty: has nothing to disclose

ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.

Learner Notifications:

Live Activity

More Information

Addiction Toxicology Case Conference - February 2025

Contains 4 Component(s)

Driving Impairment and Medical Legal Issues

Friday, February 14, 2025
1:00-2:00pm ET

Case 1: Impairment vs. Impaired Field Testing

Case 2: Am I Going Too Slow or Too Fast? Cannabis in Driving

Learning Objectives

Identify the pharmacological effects of alcohol, cannabis, opioids, and other drugs on driving ability.

Promote harm reduction and effective patient counseling approaches.

Evaluate the reliability and relevance of blood, urine, and breath testing in determining impairment at the time of driving.

Continuing Education

1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.

About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.

This webinar is free and open to the public.

Jeffrey Brent, MD, PhD, FACMT

Distinguished Clinical Professor of Medicine (Pulmonary and Critical Care) and Emergency Medicine

University of Colorado School of Medicine and Public Health

Jeffrey Brent, MD, PhD, is a Distinguished Clinical Professor of Medicine (Pulmonary and Critical Care Medicine) and Emergency Medicine at the University of Colorado Schools of Medicine and Public Health. He did his fellowship in medical toxicology at the Rocky Mountain Poison and Drug Center, where he has been both medical director and fellowship director. He is a former President of the American Academy of Clinical Toxicology and a former Board member of the American College of Medical Toxicology. Dr. Brent is the senior editor of Critical Care Toxicology: the Diagnosis and Management of the Critically Poisoned Patient, currently in its second edition. Dr. Brent is Co-Principal Investigator of ACMT’s Toxicology Investigators Consortium.

Barry Logan, PhD, F-ABFT

Executive Director, Sr. VP & Chief Scientist Forensic Sciences

Center for Forensic Science Research and Education & NMS Labs

Dr. Barry Logan is the Senior Vice President of Forensic Sciences and Chief Scientist at NMS Labs, as well as the Executive Director of the Center for Forensic Science Research and Education (CFSRE) at the Fredric Rieders Family Foundation. A Fellow of the American Board of Forensic Toxicologists (ABFT), Dr. Logan has over 190 publications exploring topics such as the effects of drugs on drivers, drug-related fatalities, and novel psychoactive substances. His current research focuses on new drug surveillance, the polydrug crisis, and the chemistry of emerging substances, leading to the founding of NPSDiscovery.org in 2018. He holds academic appointments at Indiana University, Arcadia University, and Thomas Jefferson University, and serves on the advisory board for NIDA’s National Drug Early Warning System (NDEWS). A past president of the American Academy of Forensic Sciences (AAFS), Dr. Logan was honored with TIAFT’s Alan Curry Award in 2022 for his significant contributions to forensic toxicology.

Michael G. Holland, MD, FEAPCCT, FAACT, FACOEM, FACMT, FACEP

Professor of Emergency Medicine

SUNY Upstate Medical University

Dr. Michael Holland is Clinical Professor of Emergency Medicine at SUNY Upstate Medical University in Syracuse, NY where he is on the faculty of the Medical Toxicology Fellowship Training Program and is a Consulting Medical Toxicologist at the Upstate New York Poison Center and the Onondaga County Medical Examiner’s Office-both in Syracuse, NY. Dr. Holland is also the Director of Occupational Medicine for the Saratoga Hospital Medical Group, and is the Saratoga Hospital Employee Health Medical Director, where he oversees the health and safety of over 3100 employees and staff. He also serves as Employee Health Medical Director at Glens Falls Hospital in Glens Falls, NY, covering 2500 employees. He is also Principal Medical Toxicologist at the Center for Toxicology and Environmental Health (CTEH) in Little Rock, AR.

Charles McKay, MD, FACMT

Associate Clinical Professor

University of Connecticut School of Medicine

Dr. McKay was trained in Anatomic and Surgical Pathology, Internal Medicine, Emergency Medicine, Medical Toxicology and was a Medical Director of Occupational Health and Medical Review Officer for a hospital system during more than 30 years of clinical practice, during which he provided toxicology consultation at 3 hospitals, directed a medical toxicology fellowship training program, and provided medical oversight of a regional poison control center. He provides medical legal consultation across the country on toxicology-related issues, and has testified in nearly 100 cases, many related to questions of alcohol- and drug-induced impairment.

Timothy J. Wiegand, MD, FACMT, DFASAM (Moderator)

Director and CEO, Toxicology Consulting

Medicine, Addiction Toxicology Consulting PLLC, ASAM President Elect (2025-2027)

Dr. Tim Wiegand is the Director of Toxicology Consults and President of CMO Medicine and Toxicology & Addiction Consulting. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.

Continuing Education

Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.

Nurses
Credit being awarded: 1.25 ANCC contact hours.

Commercial Support
There is no commercial support for this activity.

Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.
Jeffrey Brent, MD, PhD Faculty: has nothing to disclose
Barry Logan, PhD, Faculty: has nothing to disclose
Michael Holland, MD, Faculty: has nothing to disclose
Charles McKay, MD, Faculty: has nothing to disclose

ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.

More Information

Addiction Toxicology Case Conference - March 2025

Contains 4 Component(s)

Acute Toxic Emergencies Related to Cannabis and Marijuana Products

Friday, March 7, 2025
1:00-2:00pm ET

Case 1: Cannabis Hyperemesis Syndrome

Case 2: Stroke Mimic: And Other Varied Presentations of Cannabis Intoxication

Learning Objectives

Describe the diverse clinical presentations of acute cannabis intoxication, including Cannabis Hyperemesis Syndrome and other emergent conditions.

Describe the differential diagnosis of altered mental status in the context of cannabis intoxication.

Continuing Education

1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.

About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.

This webinar is free and open to the public.

Timothy J. Wiegand, MD, FACMT, DFASAM (Moderator)

Director and CEO, Toxicology Consulting

Medicine, Addiction Toxicology Consulting PLLC, ASAM President Elect (2025-2027)

Dr. Tim Wiegand is the Director of Toxicology Consults and President of CMO Medicine and Toxicology & Addiction Consulting. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.

Hector Barreto-Vazquez, MD

Emergency Medicine Resident

Baylor College of Medicine

Andrew Monte, MD, PhD

Scientific & Medical Director, RMPDS

Drug Center & Professor of Emergency Medicine, University of Colorado

Dr. Andrew Monte is a Professor of Emergency Medicine at the University of Colorado and the Scientific & Medical Director of the Rocky Mountain Poison & Drug Safety Center. As an emergency physician and medical toxicologist, Dr. Monte’s research focuses on precision medicine and substance abuse, aiming to enhance drug safety and effectiveness in acute care settings. His work integrates clinical outcomes from electronic health records with genomic and metabolomic data to develop predictive models of drug effects. He has a particular interest in drug-drug and drug-gene interactions, as well as the public health impacts of substance use, including cannabis liberalization and illicit drug detection. Through his research, Dr. Monte seeks to improve individualized patient care by advancing our understanding of drug response variability.

David Toomey, MD

Assistant Professor of Emergency Medicine and Medical Toxicology

University of Rochester Medical Center

David Toomey, MD earned his Doctor of Medicine degree from the University of Massachusetts Medical School and underwent residency training at the Harvard Affiliated Emergency Medicine Residency Program at Massachusetts General Hospital and Brigham and Women’s Hospital in Boston, Massachusetts. He completed his Fellowship in Medical Toxicology at the University of Rochester Medical Center in Rochester, NY where he currently serves as an Assistant Professor in the Department of Emergency Medicine and the division of Medical Toxicology.

Continuing Education

Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.

Nurses
Credit being awarded: 1.25 ANCC contact hours.

Commercial Support
There is no commercial support for this activity.

Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.
Hector Barreto-Vazquez, MD, Faculty: has nothing to disclose
Andrew Monte, MD, PhD, Faculty: has nothing to disclose
David Toomey, MD, Faculty: has nothing to disclose

ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.

More Information

Addiction Toxicology Case Conference - May 2025

Contains 4 Component(s)

Pain and Addiction

Friday, May 2, 2025
1:00-2:00pm ET

Case 1: Buprenorphine in Sickle Cell Patients

Case 2: Shoulder Replacement in a Patient on Buprenorphine

Learning Objectives

Analyze the role of buprenorphine in managing acute and chronic pain in patients with substance use disorders, including those with sickle cell disease.

Develop evidence-based approaches to perioperative pain management for patients on buprenorphine, such as those undergoing procedures like shoulder replacement.

Continuing Education

1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.

About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.

This webinar is free and open to the public.

Timothy J. Wiegand, MD, FACMT, DFASAM (Moderator)

Director and CEO, Toxicology Consulting

Medicine, Addiction Toxicology Consulting PLLC, ASAM President Elect (2025-2027)

Dr. Tim Wiegand is the Director of Toxicology Consults and President of CMO Medicine and Toxicology & Addiction Consulting. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.

Francis Coyne, MD, FAAP, FACP

Assistant Professor of Medicine and Pediatrics

University of Rochester Medical Center

Francis Coyne is an Assistant Professor of Medicine and Pediatrics at the University of Rochester Medical Center. He developed and is currently the director of URMC’s Transition Care Medicine Fellowship Program and serves as the Director of URMC’s Inpatient Transition Program. He has built on his work and advocacy for sickle cell disease with multiple projects. He currently is the PI on a project funded by Global Blood Therapeutics that has created a care-management integrated transition initiative for children with sickle cell disease. He is also the 2021-2023 George L. Engel Dean’s Teaching Fellow, developing a curriculum to address knowledge deficits in and attitudes about sickle cell disease for emergency, family medicine, internal medicine, and medicine-pediatrics residents at URMC. Dr. Coyne is also a Co-PI on a Department of Medicine Pilot grant, working towards developing an inpatient pathway for sickle cell disease care at Strong Memorial Hospital. He is double boarded in Internal Medicine and Pediatrics, specializing in care of adults with pediatric onset conditions in clinical practice. He manages both inpatient and outpatient patients of the Complex Care Center. Dr. Coyne is enthusiastic about medical education and patient care. A large portion of his work is dedicated to the care of adults with sickle cell disease.

Rebecca D. Ellis, MD

Addiction Medicine Fellow 2024-2025, Hospice & Palliative Medicine Fellow 2023-2024

University of Pittsburgh Medical Center

Dr. Rebecca Ellis is a board certified hospice and palliative care doctor and current addiction medicine fellow at University of Pittsburgh Medical Center. She completed her residency and chief residency in internal medicine at University of Washington prior to her fellowship training. Currently, she provides primary care and palliative care services for patients living with addiction at the Internal Medicine Recovery Engagement Program (IM-REP) at UPMC. She is passionate about palliative care education and expanding access to palliative care services for patients who use drugs and alcohol. She will be joining the faculty in palliative care at URMC in 2025.

Neha Pawar, MBBS

Assistant Professor, Department of Anesthesia and Perioperative Services, Department of Psychiatry, Addiction Psychiatry

University of Rochester Medical Center

Continuing Education

Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.

Nurses
Credit being awarded: 1.25 ANCC contact hours.

Commercial Support
There is no commercial support for this activity.

Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.

ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.

More Information

Addiction Toxicology Case Conference - June 2025

Contains 4 Component(s)

Pediatric Emergencies from Cannabinoid Exposure

Friday, June 6, 2025
1:00-2:00pm ET

Case 1: Pediatric Ingestion of Delta-8 Gummy
Case 2: Second-Hand Exposure

Learning Objectives

Recognize the clinical presentations of cannabinoid intoxication in pediatric patients and discuss its implications for drug testing.

Discuss the public health impact of environmental cannabinoid exposure, including respiratory and secondary exposures.

Continuing Education

1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.

About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.

This webinar is free and open to the public.

Timothy J. Wiegand, MD, FACMT, DFASAM (Moderator)

Director and CEO, Toxicology Consulting

Medicine, Addiction Toxicology Consulting PLLC, ASAM President Elect (2025-2027)

Dr. Tim Wiegand is the Director of Toxicology Consults and President of CMO Medicine and Toxicology & Addiction Consulting. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.

Diane Calello, MD, FACMT

Professor of Emergency Medicine; Executive and Medical Director, New Jersey Poison Information and Education System

Rutgers New Jersey Medical School

Dr. Calello, a New Jersey native and devotee, is currently the Director of Medical Toxicology at Morristown Medical Center and a toxicologist at the New Jersey Poison Information and Education System (NJPIES). She has lectured and published on various facets of clinical toxicology, particularly as it pertains to extracorporeal treatment, intravenous lipid emulsion, and poisoning in the young child. Dr. Calello received her BA from the College of William and Mary and her MD from New Jersey Medical School. She completed residency training in pediatrics, and fellowship training in both pediatric emergency medicine and medical toxicology at the Children’s Hospital of Philadelphia and Poison Control Center in Philadelphia. Dr. Calello is board certified in pediatrics, pediatric emergency medicine, medical toxicology, and addiction medicine.

Jeanna Marraffa, PHARMD, MPH, DABAT

Clinical Professor of Emergency Medicine

Upstate Medical University

Jeanna Marraffa is currently the Clinical Director of the Upstate New York Poison Center and a Clinical Professor in the Department of Emergency Medicine at Upstate Medical University, University Hospital in Syracuse, NY. She graduated from Union University, Albany College of Pharmacy with her Pharm.D. Degree in 2001 and have completed a one-year ASHP accredited Pharmacy Practice Residency at SUNY Upstate Medical University, Department of Pharmacy. She completed a 2-year Fellowship Program in Clinical Toxicology and Emergency Medicine in 2004 at the Upstate New York Poison Center, Department of Emergency Medicine at SUNY Upstate Medical University in Syracuse, NY and became a Diplomate of the American Board of Applied Toxicology in 2005. She received her Masters of Public Health in May 2020 from SUNY Albany. She has published numerous publications in the field of toxicology and have authored a book chapter in the 9th, 10th, 11th and upcoming 12th editions of Goldfrank’s Toxicologic Emergencies on “Dieting Agents”. She currently serves as president for the American Academy of Clinical Toxicology.

Donna Papsun, MS, D-ABFT-FT

Forensic Toxicologist & Business Scientist

NMS Labs

Donna Papsun is a forensic toxicologist and business scientist with NMS Labs in Horsham, PA. She has dual Bachelor of Science degrees in Chemistry and Forensic & Investigative Science and a Master of Science degree in Pharmacology. She is also certified as a Diplomate in Forensic Toxicology through the American Board of Forensic Toxicology and is a member of both the Society of Forensic Toxicologists (SOFT) and the American Academy of Forensic Sciences (AAFS).

Ms. Papsun has been with NMS Labs since 2008, first as a bench analyst before promotion to toxicologist in 2012. Ms. Papsun’s main area of interest is novel psychoactive substances or NPS. As one of the two leaders of NMS’s NPS strategy team, she continuously works to help maintain NMS’s leadership in identifying the newest trends in the changing landscape of the designer drug market and developing tests for their detection in forensic toxicology casework. Ms. Papsun also serves in a secondary role as a business scientist, working to align the technical and scientific expertise of NMS Labs with commercial efforts.

Continuing Education

Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.

Nurses
Credit being awarded: 1.25 ANCC contact hours.

Commercial Support
There is no commercial support for this activity.

Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.
Diane Callelo, MD, Faculty: has nothing to disclose.
Jeanna Marraffa, PHARMD, MPH, DABAT, Faculty: has nothing to disclose.
Donna Papsun, MS, D-ABFT-FT, Faculty: has nothing to disclose.

ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.

More Information

Addiction Toxicology Case Conference - July 2025

Contains 5 Component(s)

Topic coming soon!

This month's topic to be announced soon!

Friday, July 11, 2025
1:00-2:00pm ET

Case 1: TBA

Case 2: TBA

Learning Objectives

TBA

Continuing Education

1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.

About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.

This webinar is free and open to the public.

Timothy J. Wiegand, MD, FACMT, DFASAM (Moderator)

Director and CEO, Toxicology Consulting

Medicine, Addiction Toxicology Consulting PLLC, ASAM President Elect (2025-2027)

Dr. Tim Wiegand is the Director of Toxicology Consults and President of CMO Medicine and Toxicology & Addiction Consulting. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.

Continuing Education

Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.

Nurses
Credit being awarded: 1.25 ANCC contact hours.

Commercial Support
There is no commercial support for this activity.

Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.

ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.

Registration Closed
More Information

Addiction Toxicology Case Conference - August 2025

Contains 5 Component(s)

Decriminalization of Drugs

Friday, August 1, 2025
1:00-2:00pm ET

Case 1: Navigating Palliative Care in a Contaminated Drug Supply: Fentanyl Use at End of Life

Case 2: Lessons from Lisbon: Decriminalization in Practice and Policy in Portugal

Learning Objectives

Analyze how the presence of illicitly manufactured fentanyl has impacted the potential public health benefits of drug decriminalization efforts.

Describe and differentiate between various models of drug decriminalization, including their legal frameworks and implementation outcomes.

Continuing Education

1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.

About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.

This webinar is free and open to the public.

Timothy J. Wiegand, MD, FACMT, DFASAM (Moderator)

Director and CEO, Toxicology Consulting

Medicine, Addiction Toxicology Consulting PLLC, ASAM President Elect (2025-2027)

Dr. Tim Wiegand is the Director of Toxicology Consults and President of CMO Medicine and Toxicology & Addiction Consulting. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.

JoAn Laes, MD, DFASAM, FACMT

Addiction Staff Physician

Abbott Northwestern Hospital, Allina Health

JoAn Laes, MD, DFASAM, FACMT is an addiction medicine physician in Minneapolis, Minnesota, focusing on inpatient addiction medicine and toxicology consultation as well as experience in outpatient treatment of opioid and other substance use disorders. She is also a core medical toxicology faculty for the Minnesota Poison Center, Minneapolis, Minnesota, and medical director for Missions Inc. Detox facility in Plymouth, Minnesota. She is board certified in Internal Medicine, Medical Toxicology, and Addiction Medicine. She completed internal medicine residency at Hennepin County Medical Center and medical toxicology fellowship at Regions Hospital in St. Paul, Minnesota.

Amber Patt, PharmD

Clinical Toxicologist

Strong Memorial Hospital

Continuing Education

Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.

Nurses
Credit being awarded: 1.25 ANCC contact hours.

Commercial Support
There is no commercial support for this activity.

Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.

ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.

More Information

Addiction Toxicology Case Conference - October 2025

Contains 4 Component(s)

Performance Enhancing Drugs

Friday, October 3, 2025
1:00-2:00pm ET

Case 1: An Athletes Passport and Some Irregularities

Case 2: New PEDs (Performance Enhancing Drugs) and an Athlete with SUD

Learning Objectives

Describe how the Athlete’s Biologic Passport is used to detect irregularities by monitoring selected biological variables over time, and identify key variables commonly tracked in an ABP.

Explain common athlete questions about cannabis use in elite sports and WADA rules, and outline how athlete testing and specimen collection occur throughout the year.

Continuing Education

1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.

About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.

This webinar is free and open to the public.

Daniel L Overbeek, MD

Clinical Assistant Professor

Michigan State University

Daniel L. Overbeek, MD is board-certified in Emergency Medicine, Medical Toxicology, and Addiction Medicine. He completed his medical degree at Wayne State University School of Medicine, followed by an Emergency Medicine residency at the University of Michigan and a Medical Toxicology fellowship at Harvard. Dr. Overbeek is a Clinical Assistant Professor at Michigan State University and actively practices in emergency medicine, toxicology, and addiction medicine.

His clinical and research interests span a wide range of toxicology topics, including drug intoxication and overdose, alcohol and methanol exposures, kratom/mitragynine, cannabis, fentanyl, vaping and electronic cigarettes, and urine drug testing. Dr. Overbeek has published on several of these subjects and frequently consults as an expert witness in matters involving substance use, intoxication, wrongful death, negligence, and toxic torts

Timothy J. Wiegand, MD, FACMT, DFASAM (Moderator)

Director and CEO, Toxicology Consulting

Medicine, Addiction Toxicology Consulting PLLC, ASAM President Elect (2025-2027)

Dr. Tim Wiegand is the Director of Toxicology Consults and President of CMO Medicine and Toxicology & Addiction Consulting. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.

Continuing Education

Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.

Nurses
Credit being awarded: 1.25 ANCC contact hours.

Commercial Support
There is no commercial support for this activity.

Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.

ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.

More Information

Addiction Toxicology Case Conference - November 2025

Contains 4 Component(s)

Nicotine

Friday, November 7, 2025
1:00-2:00pm ET

Case 1: Adolescent Oral Nicotine Use: Early Detection and Parental Concerns

Case 2: Vaping Initiation and Dependence in Non-Traditional Users

Learning Objectives

Describe 3 different FDA approved treatments for nicotine use disorder and list common side effects associated with the use of each treatment

Describe two demographics in which nicotine use has increased rapidly in recent years, including the rising use of oral nicotine products (e.g., Zyn) among young men, and explain the underlying factors contributing to these trends.

Identify the adverse health outcomes and addiction disorders associated with tobacco and nicotine use.

Continuing Education

1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.

About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.

This webinar is free and open to the public.

Timothy J. Wiegand, MD, FACMT, DFASAM (Moderator)

Director and CEO, Toxicology Consulting

Medicine, Addiction Toxicology Consulting PLLC, ASAM President Elect (2025-2027)

Dr. Tim Wiegand is the Director of Toxicology Consults and President of CMO Medicine and Toxicology & Addiction Consulting. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.

JoAn Laes, MD, DFASAM, FACMT

Addiction Staff Physician

Abbott Northwestern Hospital, Allina Health

JoAn Laes, MD, DFASAM, FACMT is an addiction medicine physician in Minneapolis, Minnesota, focusing on inpatient addiction medicine and toxicology consultation as well as experience in outpatient treatment of opioid and other substance use disorders. She is also a core medical toxicology faculty for the Minnesota Poison Center, Minneapolis, Minnesota, and medical director for Missions Inc. Detox facility in Plymouth, Minnesota. She is board certified in Internal Medicine, Medical Toxicology, and Addiction Medicine. She completed internal medicine residency at Hennepin County Medical Center and medical toxicology fellowship at Regions Hospital in St. Paul, Minnesota.

Ismael David Yanga III, MD

Chief Medical Officer

Henry Ford Brighton Center for Recovery

Dr. Ismael David Yanga III is the Chief Medical Officer at the Henry Ford Brighton Center for Recovery. He is board-certified in Family Medicine and Addiction Medicine and brings extensive experience in clinical leadership and the treatment of substance use disorders. Dr. Yanga earned his medical degree from Wayne State University School of Medicine and completed his residency in Family Medicine at the University of Michigan Hospitals & Health Centers.

In his role, Dr. Yanga oversees clinical operations and quality of care, guiding multidisciplinary teams to provide comprehensive, evidence-based addiction treatment.

Holly A. Russell, MD

Associate Professor Family Medicine and Director of Opioid Safety

University of Rochester Medical Center

Dr. Russell earned a B.S. in Biochemistry from Boston College, and went on to serve in the Jesuit Volunteer Corps for a year in Oakland, California working as a counselor and nursing assistant at a residential treatment center for adolescents with substance abuse disorders. She obtained her M.D. degree with a Distinction in Community Service from the University of Rochester in 2007, and completed internship and residency in Family Medicine with an Area of Concentration in Research at Lancaster General Hospital in Lancaster, Pennsylvania. In 2010, she returned to the University of Rochester and completed a faculty development fellowship and a Master's of Clinical Investigation.

Dr. Russell is Board Certified in Family Medicine and Addiction Medicine and is the founder and director of the Addiction Medicine program at Highland Family Medicine. Dr. Russell is the Director of Opioid Safety for the University of Rochester Medical Center. She is also the Medical Director at Delphi Rise, a community substance use treatment program.

Continuing Education

Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.

Nurses
Credit being awarded: 1.25 ANCC contact hours.

Commercial Support
There is no commercial support for this activity.

Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.

ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.

More Information

Addiction Toxicology Case Conference - December 2025

Contains 4 Component(s)

GLP-1s

Friday, December 5, 2025
1:00-2:00pm ET

Case 1: Unexpected Substance-Use Craving Suppression With Semaglutide: Benefits Lost After Discontinuation

Case 2: Reduced Alcohol Consumption in a Non-AUD Patient Following Semaglutide Therapy.

Learning Objectives

Describe the ‘secondary effects’ some patients report after taking GLP1-agonists for weight loss.
Describe the mechanism by which GLP1-agonists cause weight loss and metabolic changes.

Continuing Education

1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.

About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.

This webinar is free and open to the public.

Timothy J. Wiegand, MD, FACMT, DFASAM (Moderator)

Director and CEO, Toxicology Consulting

Medicine, Addiction Toxicology Consulting PLLC, ASAM President Elect (2025-2027)

Dr. Tim Wiegand is the Director of Toxicology Consults and President of CMO Medicine and Toxicology & Addiction Consulting. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.

Stephanie Weiss, MD, PhD

Staff Clinician, Translational Addiction Medicine Branch

National Institute on Drug Abuse

Dr. Stephanie Weiss is the Staff Research Physician serving the National Institute on Drug Abuse’s Intramural Research Program. After earning a Ph.D. in pharmaceutical chemistry, Dr. Weiss received her medical degree in 2011. She is board certified in addiction medicine and medical toxicology and participated in the Boston University Research in Addiction Medicine Scholars Program prior to joining NIDA. Dr. Weiss is responsible for providing optimal, safe, and ethical care to study participants and clinical support toward the NIDA IRP mission of conducting inpatient and outpatient proof-of-concept human laboratory therapeutic and imaging studies for addictive disorders. Her research interests include GLP-1RAs, medication misuse, and improving interpretation of urine drug testing.

Emily Brunner, MD, DFASAM

Regional Director; Medical Director

Region VI, ASAM; Gateway Recovery Center

Dr. Emily Brunner is a board-certified family medicine physician and distinguished fellow in addiction medicine, specializing in trauma-informed, compassionate care for substance use disorders. She serves as Medical Director of Gateway Recovery and Recovering Hope and conducts trainings for the Hazelden Betty Ford Foundation. A recognized leader, she has held positions with the Minnesota Society of Addiction Medicine and currently serves on the national board of the American Society of Addiction Medicine. Dr. Brunner is a passionate advocate for expanding access to medications for opioid use disorder and improving care for patients with substance use disorders across the healthcare system. Named a Top Doctor in addiction medicine by Minnesota Magazine in 2020 and 2021, she also has a clinical interest in internet gaming and gambling disorders.

Continuing Education

Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.

Nurses
Credit being awarded: 1.25 ANCC contact hours.

Commercial Support
There is no commercial support for this activity.

Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.

ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.

More Information

2025 Addiction Toxicology Case Conference Webinar Series – Full Year Registration Package

2025 ACMT/ASAM Addiction Toxicology Case Conference Webinar Series

Addiction Toxicology Case Conference - January 2025

Benzodiazepine Tapering & Discontinuation Discussion

Learning Objectives

Continuing Education

Maryann Amirshahi, PharmD, MD, MPH, PhD, FACMT

Emergency Medicine Attending Physician, Professor Of Emergency Medicine

MedStar Washington Hospital Center, Georgetown University Hospital

Maureen Boyle, PhD

Chief Quality and Science Officer

American Society of Addiction Medicine (ASAM)

Emily Brunner, MD, DFASAM

Regional Director; Medical Director

Region VI, ASAM; Gateway Recovery Center

Alex Krotulski, PhD

Associate Director of Toxicology & Chemistry

The Center for Forensic Science Research and Education

Timothy J. Wiegand, MD, FACMT, DFASAM (Moderator)

Director and CEO, Toxicology Consulting

Medicine, Addiction Toxicology Consulting PLLC, ASAM President Elect (2025-2027)

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Continuing Education

Addiction Toxicology Case Conference - February 2025

Driving Impairment and Medical Legal Issues

Learning Objectives

Continuing Education

Jeffrey Brent, MD, PhD, FACMT

Distinguished Clinical Professor of Medicine (Pulmonary and Critical Care) and Emergency Medicine

University of Colorado School of Medicine and Public Health

Barry Logan, PhD, F-ABFT

Executive Director, Sr. VP & Chief Scientist Forensic Sciences

Center for Forensic Science Research and Education & NMS Labs

Michael G. Holland, MD, FEAPCCT, FAACT, FACOEM, FACMT, FACEP

Professor of Emergency Medicine

SUNY Upstate Medical University

Charles McKay, MD, FACMT

Associate Clinical Professor

University of Connecticut School of Medicine

Timothy J. Wiegand, MD, FACMT, DFASAM (Moderator)

Director and CEO, Toxicology Consulting

Medicine, Addiction Toxicology Consulting PLLC, ASAM President Elect (2025-2027)

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Continuing Education

Addiction Toxicology Case Conference - March 2025

Acute Toxic Emergencies Related to Cannabis and Marijuana Products

Learning Objectives

Continuing Education

Timothy J. Wiegand, MD, FACMT, DFASAM (Moderator)

Director and CEO, Toxicology Consulting

Medicine, Addiction Toxicology Consulting PLLC, ASAM President Elect (2025-2027)

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Hector Barreto-Vazquez, MD

Emergency Medicine Resident

Baylor College of Medicine

Andrew Monte, MD, PhD

Scientific & Medical Director, RMPDS

Drug Center & Professor of Emergency Medicine, University of Colorado

David Toomey, MD

Assistant Professor of Emergency Medicine and Medical Toxicology

University of Rochester Medical Center

Continuing Education

Addiction Toxicology Case Conference - May 2025

Pain and Addiction

Learning Objectives

Continuing Education

Timothy J. Wiegand, MD, FACMT, DFASAM (Moderator)

Director and CEO, Toxicology Consulting

Medicine, Addiction Toxicology Consulting PLLC, ASAM President Elect (2025-2027)

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Francis Coyne, MD, FAAP, FACP

Assistant Professor of Medicine and Pediatrics